Primary Care
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7528.1310 (Published 01 December 2005) Cite this as: BMJ 2005;331:1310
Related articles
- This Week In The BMJ Published: 01 December 2005; BMJ 331 doi:10.1136/bmj.331.7528.0-b
- Research Published: 14 July 2009; BMJ 339 doi:10.1136/bmj.b2538
- Editorial Published: 21 September 2002; BMJ 325 doi:10.1136/bmj.325.7365.607
- Editorial Published: 01 June 2002; BMJ 324 doi:10.1136/bmj.324.7349.1287
- Primary Care Published: 22 September 2001; BMJ 323 doi:10.1136/bmj.323.7314.666
- Fillers Published: 11 November 2000; BMJ 321 doi:10.1136/bmj.321.7270.1190
- Information In Practice Published: 26 June 2003; BMJ 326 doi:10.1136/bmj.326.7404.1439
- Paper Published: 25 July 1998; BMJ 317 doi:10.1136/bmj.317.7153.245
- Primary Care Published: 11 May 2002; BMJ 324 doi:10.1136/bmj.324.7346.1132
- Fillers Published: 09 May 1998; BMJ 316 doi:10.1136/bmj.316.7142.1467
- Paper Published: 30 August 1997; BMJ 315 doi:10.1136/bmj.315.7107.510
- Practice Published: 04 January 2007; BMJ 334 doi:10.1136/bmj.39014.468900.BE
- Paper Published: 22 July 1995; BMJ 311 doi:10.1136/bmj.311.6999.222
- Letter Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1474-b
- Letter Published: 15 June 2006; BMJ 332 doi:10.1136/bmj.332.7555.1451-b
- Letter Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1473-d
- Letter Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1474
- Research Published: 30 March 2016; BMJ 352 doi:10.1136/bmj.i1450
- Research Published: 13 July 2016; BMJ 354 doi:10.1136/bmj.i3477
- Primary Care Published: 21 October 2004; BMJ 329 doi:10.1136/bmj.38232.680567.EB
- PRIMARY CARE Published: 08 October 2004; BMJ doi:10.1136/bmj.38232.680567.EB
- Letter Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1474-c
- General Practice Published: 03 February 1996; BMJ 312 doi:10.1136/bmj.312.7026.287
- Letter Published: 14 November 1998; BMJ 317 doi:10.1136/bmj.317.7169.1389
- Paper Published: 25 January 1997; BMJ 314 doi:10.1136/bmj.314.7076.257
- Paper Published: 22 June 1996; BMJ 312 doi:10.1136/bmj.312.7046.1563
- Letter Published: 15 December 2005; BMJ 331 doi:10.1136/bmj.331.7530.1474-a
See more
- Introductory AddressProv Med Surg J October 03, 1840, s1-1 (1) 1-4; DOI: https://doi.org/10.1136/bmj.s1-1.1.1
- Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond'sProv Med Surg J October 03, 1840, s1-1 (1) 10-13; DOI: https://doi.org/10.1136/bmj.s1-1.1.10
- Mr. Warburton's Bill for the Regulation of the Medical ProfessionProv Med Surg J October 03, 1840, s1-1 (1) 13-15; DOI: https://doi.org/10.1136/bmj.s1-1.1.13
- An Atlas of Plates, illustrative of the Principles and Practice of Obstetric Medicine and Surgery, with descriptive LetterpressProv Med Surg J October 03, 1840, s1-1 (1) 4; DOI: https://doi.org/10.1136/bmj.s1-1.1.4
- A Practical Treatise on the Diseases peculiar to Women, illustrated by Cases, &cProv Med Surg J October 03, 1840, s1-1 (1) 4-5; DOI: https://doi.org/10.1136/bmj.s1-1.1.4-a
Cited by...
- Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
- Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care
- Non-steroidal anti-inflammatory use in the XV Pan-American Games (2007)
- Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis
- The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs
- Dyspepsia and Helicobacter pylori
- Culture-Independent Analysis of Indomethacin-Induced Alterations in the Rat Gastrointestinal Microbiota
- Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency
- Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Study conclusions do not reflect findings for celecoxib
- Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Why were patients at major risk excluded?
- Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib?
- Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: How strong is the evidence?
- Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option